The prevalence of diabetes is rising in the Asia Pacific region .However, the diagnosis rate remains low. So, an increase in awareness programs and the availability of better healthcare services are likely to propel the market. The market for diabetes drugs in the Asia Pacific is expected to grow at a CAGR of 10.82% during the forecast period of 2019-2027.

ASIA PACIFIC DIABETES DRUGS MARKET FORECAST 2019-2027

Asia Pacific Diabetes Drugs Market is segmented by Diabetes Type( Type 1, Type 2) by Product Class( Insulin (Fast Acting Insulin, Intermediate Acting Insulin, Long-acting Insulin) Non-Insulin (DPP-4 Inhibitor, GLP-1 Receptors Agonists, SGLT-2 Inhibitors)) & by Geography

Request free sample

Report Summary

The prevalence of diabetes is rising in the Asia Pacific region .However, the diagnosis rate remains low. So, an increase in awareness programs and the availability of better healthcare services are likely to propel the market. The market for diabetes drugs in the Asia Pacific is expected to grow at a CAGR of 10.82% during the forecast period of 2019-2027.

Emerging countries in the Asia Pacific such as China and India offer immense opportunities for leading players in the market, as these countries consist of a large pool of under-served patients. The diabetes market in China is growing at a rapid rate and is expected to be larger than Japan by the end of the forecast period. Global vendors are expanding their business in this region by focusing on strategic mergers with domestic distribution partners and suppliers to enhance their distribution and sales channels. The main focus is on India and China as they offer vast growth potential. Nearly half of the people with diabetes remain undetected, accounting for complications at the time of diagnosis. Hence, pharmacologic care needs to be individualized with early consideration of combination therapy, regular exercise, yoga, mindful eating and stress management so as to form a cornerstone in the management of diabetes.

Prominent players in the Asia Pacific diabetes drugs market are Pfizer, AstraZeneca Plc., B.Braun Melsungen Ag, Sanofi, Diavacs Inc., Xoma Corp., Glaxosmithkline, Albireo Pharma Inc., Merck, Novo Nordisk A/S, Macrogenics Inc. and Astellas Pharma.

 

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

    Table of Contents

    1. RESEARCH SCOPE
      • STUDY GOALS
      • SCOPE OF THE MARKET STUDY
      • WHO WILL FIND THIS REPORT USEFUL?
      • STUDY AND FORECASTING YEARS
    2. RESEARCH METHODOLOGY
      • SOURCES OF DATA
        • SECONDARY DATA
        • PRIMARY DATA
      • TOP-DOWN APPROACH
      • BOTTOM-UP APPROACH
      • DATA TRIANGULATION
    3. EXECUTIVE SUMMARY
      • MARKET SUMMARY
      • KEY FINDINGS
        • RISING PREVALENCE OF TYPE 2 DIABETES
        • INSULIN MARKET IS ANTICIPATED TO GENERATE HIGHEST REVENUE
    1. MARKET DETERMINANTS
      • MARKET DRIVERS
        • INCREASE IN PREVALENCE OF DIABETES
        • ADVANCES IN INSULIN TECHNOLOGY
        • GROWING ELDERLY POPULATION
      • MARKET RESTRAINTS
        • LACK OF AWARENESS AMONG PEOPLE
        • COST SENSITIVITY ISSUES
      • MARKET OPPORTUNITIES
        • DEVELOPMENT OF NEW FORMULATIONS
        • INCREASING RESEARCH AND DEVELOPMENT
      • MARKET CHALLENGES
        • FIERCE MARKET COMPETITION
        • RISING CONCERNS IN SCIENTIFIC COMMUNITY
        • GAPS IN NATIONAL-LEVEL DIABETES MANAGEMENT PLANS
        • POOR STORAGE CONDITIONS AND DISTRIBUTION POLICIES FOR INSULIN
    1. MARKET SEGMENTATION
      • MARKET BY DIABETES TYPE 2019-2027
        • TYPE 1
        • TYPE 2
      • MARKET BY PRODUCT CLASS 2019-2027
        • INSULIN
          • FAST ACTING INSULIN
          • INTERMEDIATE ACTING INSULIN
          • LONG-ACTING INSULIN
        • NON-INSULIN
          • DPP-4 INHIBITOR
          • GLP-1 RECEPTORS AGONISTS
          • SGLT-2 INHIBITORS
          • OTHER NON-INSULIN DRUGS
    1. KEY ANALYTICS
      • PORTER’S FIVE FORCE ANALYSIS
        • THREAT OF NEW ENTRANTS
        • THREAT OF SUBSTITUTE
        • BARGAINING POWER OF SUPPLIERS
        • BARGAINING POWER OF BUYERS
        • THREAT OF COMPETITIVE RIVALRY
      • OPPORTUNITY MATRIX
      • ETYMOLOGY OF DIABETES DRUGS MARKET
      • LEGAL, POLICY AND REGULATORY ISSUES
    2. GEOGRAPHICAL ANALYSIS
      • ASIA-PACIFIC (APAC)
        • CHINA
        • INDIA
        • AUSTRALIA
        • JAPAN
        • SOUTH KOREA
        • INDONESIA
        • MALAYSIA
        • PHILIPPINES
        • THAILAND
        • VIETNAM
        • REST OF ASIA-PACIFIC (ROAPAC)
    1. COMPANY PROFILES
      • ELI LILLY AND COMPANY
        • OVERVIEW
        • PRODUCTS PORTFOLIO
        • SWOT ANALYSIS
        • STRATEGIC INITIATIVES
      • ASTRAZENECA
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SWOT ANALYSIS
        • STRATEGIC INITIATIVES
      • BRAUN MELSUNGEN AG
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC ANALYSIS
      • NOVO NORDISK A/S
        • OVERVIEW
        • PRODUCTS PORTFOLIO
        • SWOT ANALYSIS
        • STRATEGIC INITIATIVES
      • SANOFI
        • OVERVIEW
        • PRODUCTS PORTFOLIO
        • SWOT ANALYSIS
        • STRATEGIC INITIATIVES
      • DIAVACS INC.
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SWOT ANALYSIS
      • XOMA CORP.
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SWOT ANALYSIS
        • STRATEGIC INITIATIVES
      • ALBIREO PHARMA INC.
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SWOT ANALYSIS
      • MACROGENICS, INC.
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SWOT ANALYSIS
      • ASTELLAS PHARMA
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SWOT ANALYSIS
        • STRATEGIC INITIATIVES
      • GLAXOSMITHKLINE
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SWOT ANALYSIS
      • MERCK
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SWOT ANALYSIS
        • STRATEGIC INITIATIVES
      • PFIZER
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SWOT ANALYSIS
        • STRATEGIC INITIATIVES
      • XERIS PHARMACEUTICALS
        • OVERVIEW
        • PRODUCT PORTFOLIO
        • SWOT ANALYSIS
        • STRATEGIC INITIATIVES

    TABLE LIST

    TABLE  1      ASIA PACIFIC DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

    TABLE  2      ASIA PACIFIC DIABETES DRUGS MARKET BY DIABETES TYPES 2019-2027, ($ MILLION)

    TABLE  3      ASIA PACIFIC DIABETES DRUGS MARKET IN TYPE 1 DIABETES 2019-2027 ($ MILLION)

    TABLE  4      ASIA PACIFIC DIABETES DRUGS MARKET IN TYPE 2 DIABETES 2019-2027 ($ MILLIONS)

    TABLE  5      ASIA PACIFIC DIABETES DRUGS MARKET BY PRODUCT CLASS 2019-2027 ($ MILLIONS)

    TABLE  6      ASIA PACIFIC DIABETES DRUGS MARKET IN INSULIN TYPE 2019-2027 ($ MILLION)

    TABLE  7      ASIA PACIFIC DIABETES DRUGS MARKET IN INSULIN BY TYPES 2019-2027 ($ MILLION)

    TABLE  8      ASIA PACIFIC INSULIN MARKET IN FAST ACTING INSULIN 2019-2027 ($ MILLION)

    TABLE  9      ASIA PACIFIC INSULIN MARKET IN INTERMEDIATE ACTING INSULIN 2019-2027 ($ MILLION)

    TABLE  10    ASIA PACIFIC INSULIN MARKET IN LONG ACTING INSULIN 2019-2027 ($ MILLION)

    TABLE  11    ASIA PACIFIC DIABETES DRUGS MARKET IN NON-INSULIN DRUGS 2019-2027 ($ MILLION)

    TABLE  12    ASIA PACIFIC DIABETES DRUGS MARKET IN NON-INSULIN DRUGS BY TYPES 2019-2027 ($ MILLION)

    TABLE  13    ASIA PACIFIC NON-INSULIN DRUGS MARKET IN  DPP-4 INHIBITOR 2019-2027 ($ MILLION)

    TABLE  14    ASIA PACIFIC NON-INSULIN DRUGS MARKET IN  GLP-1 RECEPTORS AGONISTS 2019-2027 ($ MILLION)

    TABLE  15    ASIA PACIFIC NON-INSULIN DRUGS MARKET IN  SGLT-2 INHIBITORS 2019-2027 ($ MILLION)

    TABLE  16    ASIA PACIFIC NON-INSULIN DRUGS MARKET IN  OTHER NON-INSULIN DRUGS 2019-2027 ($ MILLION)

    TABLE  17    ASIA-PACIFIC DIABETES DRUGS MARKET BY COUNTRY 2019-2027 ($ MILLION)

    FIGURE LIST

    FIGURE  1    ASIA PACIFIC DIABETES DRUGS MARKET 2019-2027 ($ BILLION)

    FIGURE  2    ASIA PACIFIC DIABETES DRUGS MARKET, BY TYPE 2 DIABETES 2019-2027 ($ MILLION)

    FIGURE  3    AVERAGE LIFE EXPECTANCY AT BIRTH IN 2017, BY GENDER (IN YEARS)

    FIGURE  4    PORTER’S FIVE FORCES ANALYSIS OF DIABETES DRUGS MARKET

    FIGURE  5    CHINA DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

    FIGURE  6    INDIA DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

    FIGURE  7    AUSTRALIA DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

    FIGURE  8    JAPAN DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

    FIGURE  9    SOUTH KOREA DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

    FIGURE  10  INDONESIA DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

    FIGURE  11  MALAYSIA DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

    FIGURE  12  PHILIPPINES DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

    FIGURE  13  THAILAND DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

    FIGURE  14  VIETNAM DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

    FIGURE  15  REST OF ASIA-PACIFIC DIABETES DRUGS MARKET 2019-2027 ($ MILLION)

    Segmentation

    1. MARKET SEGMENTATION
      • MARKET BY DIABETES TYPE 2019-2027
        • TYPE 1
        • TYPE 2
      • MARKET BY PRODUCT CLASS 2019-2027
        • INSULIN
          • FAST ACTING INSULIN
          • INTERMEDIATE ACTING INSULIN
          • LONG-ACTING INSULIN
        • NON-INSULIN
          • DPP-4 INHIBITOR
          • GLP-1 RECEPTORS AGONISTS
          • SGLT-2 INHIBITORS
          • OTHER NON-INSULIN DRUGS
    1. GEOGRAPHICAL ANALYSIS
      • ASIA-PACIFIC (APAC)
        • CHINA
        • INDIA
        • AUSTRALIA
        • JAPAN
        • SOUTH KOREA
        • INDONESIA
        • MALAYSIA
        • PHILIPPINES
        • THAILAND
        • VIET NAM
        • REST OF ASIA-PACIFIC (ROAPAC)

    Request Free Sample

    To request a free sample copy of this report, please complete the form below :

    We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

      Choose License Type

      Get In Touch

      Inquire Before Buying

      Customization

      Inkwood Research delivers customized reports as per the client's requirement to provide them with an edge in the competitive market

      Request Customization

      RELATED REPORTS